FXR (encoded by Nr1h4) is a ligand-activated transcriptional factor expressed in diverse tissues including the adrenal gland, kidney, stomach, duodenum, jejunum, ileum, colon, gall bladder, liver and macrophages, as well as in white and brown adipose depots 1 . BAs function as endogenous ligands for FXR such that enteric and systemic release of BAs induces FXR-directed changes in gene expression networks [2] [3] [4] [5] [6] [7] [8] . The complex role of FXR in metabolic homeostasis is evident in studies on whole body Nr1h4 −/− mice. On a normal chow diet, Nr1h4 −/− mice develop metabolic defects including hyperglycemia and hypercholesterolemia, but, conversely, they exhibit improved glucose homeostasis compared with control mice when challenged with a high-fat diet (HFD) 9, 10 . Similar contrary effects are seen with systemic FXR agonists, with beneficial effects observed in chow-fed mice, whereas exacerbated weight gain and glucose intolerance is seen in diet-induced obesity (DIO) mice 11, 12 .
In the liver, FXR activation suppresses hepatic BA synthesis, alters BA composition, reduces the BA pool size [13] [14] [15] and contributes to liver regeneration 16 as well as glucose, lipid and cholesterol homeostasis 17, 18 . Consistent with this, activation of hepatic FXR by the synthetic BA 6α-ethyl chenodeoxycholic acid is beneficial in the treatment of diabetes, nonalcoholic fatty liver disease and primary biliary cirrhosis 19, 20 .
In addition to expression in the liver, FXR is also expressed in the intestine, where it regulates production of the endocrine hormone Fgf15 (FGF19 in humans), which in conjunction with hepatic FXR is thought to control BA synthesis, transport and metabolism [21] [22] [23] . Although intestinal FXR activity is also involved in reducing overgrowth of the microbiome during feeding 24, 25 , the role of food-activated (prandial) intestinal FXR in body physiology is poorly understood.
In response to a meal, bile acids are secreted into the intestine from the gall bladder and acutely activate intestinal FXR. We thus reasoned that it might be feasible to mimic food activation of intestinal FXR by treating mice with a nonabsorbed synthetic FXR agonist. As we now show, orally delivered Fex 26 is poorly absorbed into the circulation, resulting in intestinally restricted FXR activation. Despite this restricted activation, Fex treatment of DIO mice produces a new, striking metabolic profile that includes reduced weight gain, decreased inflammation, browning of WAT and increased insulin sensitization. The beneficial whole-body efficacy achieved with Fex suggests intestinal FXR therapy as a promising and potentially safer approach to systemic FXR agonism in the treatment of insulin resistance and metabolic syndrome.
RESULTS

Orally active Fex shows minimal systemic exposure
We previously reported the development and in vitro characterization of Fex as a specific and potent FXR agonist 26 . In exploring the in vivo effects, we discovered that due to poor absorption, oral (p.o.) and intraperitoneal (i.p.) drug delivery produced very different effects (Fig. 1a,b) . The i.p. Fex treatment (100 mg kg −1 for 5 d) produced robust induction of the FXR target gene Nr0b2 (which encodes for SHP, small heterodimer partner) in the liver, kidney and gut, whereas a r t i c l e s 1 6 0 VOLUME 21 | NUMBER 2 | FEBRUARY 2015 nature medicine Fig. 1d and Supplementary  Fig. 1 ). Quantification revealed that drug levels were lower by an order of magnitude after acute p.o. treatment compared with i.p. treatment (Fig. 1a,b) , with serum levels of Fex after p.o. administration below the 25 nM half-maximum effective concentration of Fex 26 , in keeping with the lack of target gene activation in kidney and liver.
Fex counters obesity and metabolic syndrome
To investigate the systemic effects of enteric FXR activation, mice were subjected to 5 weeks of daily Fex treatment by oral gavage (100 mg kg −1 Fex). Chronically treated chow-fed mice were indistinguishable from vehicle-treated mice in terms of weight gain, basal metabolic activity and glucose tolerance (Supplementary Fig. 2 ). In contrast, Fex-treated DIO mice (C57BL/6J mice after 14 weeks of a 60% fat diet) showed a dose-dependent reduction in weight gain ( Fig. 2a and Supplementary Fig. 3b ) with no signs of intestinal toxicity ( Supplementary Fig. 4 ). The reduction in weight gain of Fex-treated mice was largely attributed to reduced overall fat mass, with significant reductions in wet weights of both subcutaneous (inguinal) and visceral (gonadal and mesenteric) adipose depots (Fig. 2b,c) . Consistent with reduced adiposity, Fex-treated mice showed significant improvements in their endocrine and metabolic profiles including reduced glucose, insulin, leptin, cholesterol and resistin levels ( Fig. 2d and Supplementary Fig. 3a ). In addition, serum levels of the inflammatory cytokines tumor necrosis factor-α (Tnf-α), interleukin (Il)-1α, Il-1β, Il-17 and mast cell protease-1 (Mcp-1) were markedly decreased (Fig. 2e) . Furthermore, Fex treatment induced dose-dependent improvements in glucose tolerance and insulin sensitivity in DIO mice (measured by glucose and insulin tolerance tests; Fig. 2f ,g and Supplementary Fig. 3c ), but had no effect in normal chow-fed mice (Supplementary Fig. 2d) . Notably, these Fex-induced changes in gene expression and improvements in metabolic homeostasis were abrogated in Fex-treated Nr1h4 −/− mice, establishing the FXR dependence of the observed effects ( Supplementary Fig. 5 ).
Fex enhances energy expenditure in brown adipose tissue As the differential weight effect was not attributable to a difference in food intake between vehicle and Fex-treated mice (Fig. 3a) , we compared the metabolic rates of weight-matched mice. Fex-treated DIO mice had consistently higher oxygen consumption (VO 2 ) and exhaled more carbon dioxide (VCO 2 ) than vehicle-treated controls (Fig. 3b,c) , but displayed similar respiratory exchange ratios, suggesting enhanced use of both sugar and fat (Supplementary Fig. 6 ).
As determined by ambulatory counts, Fextreated mice were more active than control mice, which may be a reflection of their lower body weights, supporting increased energy expenditure (Fig. 3d) . Consistent with increased energy expenditure, Fex treatment increased the core body temperature of the mice by approximately 1.5 °C (Fig. 3e) . In addition, the prominent accumulation of lipid vesicles in brown adipose tissue (BAT) of vehicle-treated DIO mice was markedly reduced in Fex-treated mice (Fig. 3f) . Gene expression analysis confirmed the induction of Esrrg (encoding estrogen receptor related-γ (ERR-γ)), Ppargc1a (encoding PGC-1α, peroxisome proliferator-activated receptor γ coactivator 1α) and Ppargc1b (encoding PGC-1β), as well as a number of their target genes involved in thermogenesis, mitochondrial biogenesis and fatty acid oxidation in BAT (Fig. 3g) . Moreover, Fex treatment increased the phosphorylation level of p38 ( Fig. 3h and Supplementary  Fig. 7a ), which has been shown to stabilize PGC-1α, a key coactivator of the thermogenic transcriptional program in BAT 27 . A comparison of the transcriptional changes induced by Fex in inguinal, gonadal and brown adipose depots revealed coordinated changes that selectively enhance oxidative phosphorylation activity in BAT, suggesting that BAT is a key contributor to the increased energy expenditure and thermogenesis (Supplementary Fig. 7b ). Consistent with this suggestion, KEGG pathway analysis of Fex-induced transcriptional changes in BAT identified oxidative phosphorylation and the chemokine/cytokine signaling pathway as significantly changed (Supplementary Fig. 7c,d ), whereas increased protein kinase A activity was also seen in Fex-treated mice ( Supplementary  Fig. 7e ). Furthermore, serum lactate levels were significantly reduced in Fex-treated DIO mice, suggesting that body-wide energy metabolism is shifted toward a more oxidative state (Supplementary Fig. 7f) . Thus, the marked reductions in lipids, increased protein kinase A activity and p38 phosphorylation, as well as increased core body temperature, indicate a coordinated activation of thermogenesis in BAT in Fex-treated DIO mice. Fex induces Fgf15 and alters BA composition RNA-seq of intestinal tissues was used to explore the mechanisms through which Fex might contribute to systemic changes in energy expenditure and metabolic rate. KEGG pathway analysis revealed induction of multiple metabolic pathways including peroxisome proliferator-activated receptor and adipocytokine signaling in both ileum and colon (Supplementary Fig. 8a ). Overlap of Fex-induced expression changes with previously identified intestinal FXR binding sites 28 identified a subset of genes as potential direct FXR targets (Fig. 4a) . Within this subset, Fgf15 was found to be markedly upregulated by Fex. In addition to established FXR target genes such as Lpl, other genes potentially regulated by FXR were identified, including the circadian regulator Per1 (Fig. 4a) .
As it encodes an intestinal endocrine hormone, Fgf15 induction is of particular interest because Fgf15 is known to activate the thermogenic program in BAT 29 . Fgf15 also negatively regulates BA synthesis through suppression of hepatic Cyp7a1, which encodes the rate-limiting enzyme for BA synthesis 22, 23, 30 . As expected, endogenous serum Fgf15 levels were too low to be detected in vehicletreated mice. However, prolonged intestinal FXR activation by Fex treatment resulted in a sustained increase in Fgf15 production. We were able to measure an increase in circulating Fgf15 that accompanied the increase in mRNA expression in ileum (Fig. 4b,c) . Consistent with this increase in serum Fgf15, hepatic Cyp7a1 was significantly repressed at both the mRNA and protein level after chronic Fex treatment, whereas the expression of Cyp8b1 and Cyp27a1 were not significantly affected. However, the expression of Cyp7b1, encoding a key enzyme in the alternate (acidic) pathway of BA synthesis, which bypasses Cyp7a1, was increased ( Fig. 4d and Supplementary Fig. 8b) .
Notably, expression of the well-established hepatic FXR target genes
Nr0b2 and Abcb11 (encoding Bsep, bile salt export pump) was not altered, further demonstrating the absence of liver FXR activation after chronic Fex treatment (Fig. 4d) and implying that other pathways, such as Fgf15, mediate changes in hepatic gene expression.
Despite the apparent absence of hepatic FXR activation, Fex treatment produced striking changes in the composition of the BA pool. In addition to reducing the size of the BA pool, Fex treatment changed the relative proportions of circulating BAs, most notably decreasing the fraction of taurocholic acid and increasing the fraction of the secondary BA, lithocholic acid (Fig. 4e,f and Supplementary Table 1) . These changes are consistent with increased intestinal FXR activation, including the effects of increased circulating Fgf15 on BA synthesis in the liver. Indeed, decreased serum taurocholic acid has been previously reported in mice expressing a constitutively activated FXR transgene in intestine, as well as after injection of FGF19, the human analog of Fgf15 (ref. 31) . Furthermore, changes in BA synthesis away from cholic acid toward chenodeoxycholic acid and its derivatives, including lithocholic acid, were observed upon FGF19 treatment 31 , consistent with a reduction in hepatic Cyp7a1 and an increase in Cyp7b1 expression. FXR activation has been reported to enhance expression of genes involved in mucosal defense and intestinal barrier function 25, 32 . Consistent with these reports, mice showed reduced intestinal permeability, as measured by fluorescein isothiocyanate (FITC)-dextran leakage into the serum, and increased expression of mucosal defense genes Ocln (encoding occludin) and Muc2 after chronic treatment with Fex (Fig. 4g,h) .
Although Fex does not activate the G protein-coupled BA receptor Tgr5 (encoded by Gpbar1) (Supplementary Fig. 9 ), the pronounced changes in BAs suggested that this pathway might contribute to the observed physiologic effects. Notably, treatment of mice fed an HFD with the intestinally restricted Tgr5 agonist L7550379 did not induce metabolic changes, whereas treatment with the systemic Tgr5 agonist RO5527239 improved glucose homeostasis, as measured by glucose tolerance test and insulin secretion (Supplementary Fig. 10 ). These findings suggested that Tgr5 activation outside of the intestine may contribute to the beneficial effects of Fex treatment 33 ( Supplementary  Fig. 10b,d-f) . To address this possibility, Gpbar1 −/− mice fed an HFD were chronically treated with Fex (100 mg kg −1 d −1 p.o. for 5 weeks). As seen in wild-type mice, Fex treatment induced multiple FXR target genes in the ileum of Gpbar1 −/− mice including Fgf15, resulting in lowered serum BA levels ( Supplementary Fig. 11a,b) . In this Gpbar1 −/− background, Fex treatment induced moderate improvements in fasting glucose levels and glucose tolerance (Supplementary Fig. 11c ). In addition, somewhat blunted increases in core body temperature and metabolic rate, correlating with the induction of thermogenic genes in BAT, were observed ( Supplementary Fig. 11d,e) , suggesting that these effects do not require Tgr5 activation. In contrast to wild-type mice, no significant changes in weight gain or insulin sensitivity were observed in Fex-treated Gpbar1 −/− mice, and altered gene expression patterns were seen in the liver and muscle, indicating involvement of the Tgr5 pathway (Supplementary Fig. 11f-j) . In particular, the antilipogenic effects of Fex in the liver seem to require Tgr5 activation, as key hepatic lipogenic genes and liver triglyceride content were not affected by Fex treatment (Supplementary Fig. 11h,i) .
Fex induces browning of WAT During obesity, adipose tissue expands by hyperplastic and/or hypertrophic growth, is chronically inflamed and produces inflammatory cytokines that ultimately contribute to systemic metabolic dysregulation. After chronic treatment of DIO mice with Fex, the crosssectional area of adipocytes in visceral depots, including gonadal and mesenteric adipocytes, was markedly reduced compared to vehicle (Fig. 5a ). An investigation of signaling pathways implicated in dietinduced inflammation identified reduced levels of IKK-ε and TANKbinding kinase 1 in Fex-treated DIO mice (Fig. 5b and Supplementary  Fig. 12a ). These noncanonical IκB kinases were recently shown to have crucial roles in energy expenditure as a consequence of adipose tissue inflammation upon diet-induced obesity 34 . In addition, activation of the mammalian target of rapamycin complex 1 (mTORC1) pathway, a key lipogenic pathway activated by an HFD, was reduced in Fex-treated gonadal WAT, as evidenced by reduced S6 kinase phosphorylation (Fig. 5b) . Consistent with reduced adiposity, gene expression of the inflammatory cytokines was reduced in visceral and brown adipose depots of Fex-treated mice compared to vehicle ( Fig. 5c and Supplementary Fig. 12b) .
Brown adipose-driven adaptive thermogenesis is fueled by mitochondrial oxidation of free fatty acids (FFAs) released from triglyceride stores into the circulation, predominantly by the action of hormone-sensitive lipase (Hsl). Low levels of Hsl phosphorylation were seen in visceral and subcutaneous adipose depots from control mice, as expected due to desensitization of the β-adrenergic pathway in WAT during obesity 35, 36 . In contrast, when compared with vehicle treatment, a pronounced increase in Hsl phosphorylation and FFA levels (Fig. 5d,f) , accompanied by increased serum catecholamine levels and β3-adrenergic receptor expression (Fig. 5c,e) , was observed after chronic treatment with Fex. As β-adrenergic receptor activation has been shown to induce brown fat-like cells in inguinal adipose tissue, and these cells have been associated with resistance to dietinduced obesity and improved glucose metabolism [37] [38] [39] [40] , we examined Ucp1 expression in inguinal adipose tissue. Immunohistochemistry revealed a substantial increase in the abundance of multilocular, Ucp1-expressing adipocytes in Fex-treated animals (Fig. 5g) . Furthermore, Fex treatment increased the expression of brown fatlike signature genes and increased respiratory capacity in the stromal vascular fraction from inguinal adipose tissue ( Supplementary  Fig. 13a,b) . These results indicate that Fex, unlike systemic FXR ligands, induces a distinct coordinated metabolic response that enhances β-adrenergic signaling to promote lipolysis and mobilizes fatty acids for oxidation in BAT and the 'browning' of cells in WAT.
Fex improves insulin responsiveness
To probe the mechanism through which chronic Fex treatment improved glucose homeostasis, we carried out hyperinsulinemiceuglycemic clamp studies. No differences in basal hepatic glucose production (HGP), glucose disposal rate (GDR), insulin-stimulated GDR, FFA suppression and fasting insulin levels were observed between weight-matched cohorts (generated by treating initially heavier mice (2-3 g) with Fex; Fig. 6a-c and Supplementary  Fig. 14) . However, Fex-treated mice displayed a marked increase in insulin-mediated suppression of HGP compared with control DIO mice (Fig. 6d) . Thus, while the attenuated weight gain likely contributes to improved glucose clearance in Fex-treated mice, this improvement in hepatic glucose suppression indicates enhanced liver insulin sensitivity after Fex treatment.
Liver insulin resistance has been linked to obesity-induced hepatic steatosis 41 . Histological examination of liver tissue from Fex-treated DIO mice revealed a reduction in lipid droplets compared with controls, indicating amelioration of hepatic steatosis (Fig. 6e) . Consistent with this histology, a marked decrease in hepatic triglycerides and reduced hepatic expression of gluconeogenic and lipogenic genes were seen after chronic Fex treatment (Fig. 6f,g ). Furthermore, decreased serum alanine aminotransferase (ALT) levels were measured in Fex-treated mice, indicative of reduced liver damage induced by an HFD (Fig. 6h) . Thus, in DIO mice, Fex promotes hepatic insulin sensitization, reduced steatosis, improved metabolic markers, decreased ALT and enhanced BAT activity.
DISCUSSION
Here we show that the gut-biased FXR agonist Fex has substantial metabolic benefits in a mouse model of obesity. Fex protects against diet-induced weight gain by promoting the expression of genes involved in thermogenesis, mitochondrial biogenesis and fatty acid oxidation. Linked to the unexpected browning of white adipose, Fex lowers inflammatory cytokine levels while upregulating β-adrenergic signaling. These changes seem to be mediated in part by a change in BA levels and composition. In addition, intestinal-specific FXR activation corrected numerous obesity-related defects, enhanced glucose tolerance and lowered hepatic glucose production. Notably, these physiologic changes are dependent on FXR expression and result npg a r t i c l e s 1 6 4 VOLUME 21 | NUMBER 2 | FEBRUARY 2015 nature medicine in hepatic insulin sensitization and BAT activation, properties not formerly associated with this class of drug. How might this be achieved? The initial event triggering systemic metabolic activation is probably coordinated by Fgf15, a key regulator of energy expenditure reported to increase metabolic rate and improve glucose and lipid homeostasis without significant changes in food intake 29, 42 . The absence of a change in food intake is notable, as failure of appetite control is a major reason for weight gain 43 . Thus, systemic increases in energy expenditure, as seen in Fex-treated mice, may offer a viable alternative for obesity treatments. However, this explanation alone is not sufficient, as systemic FXR agonists, while robustly inducing Fgf15, do not display many of the benefits of gut-biased FXR activation.
One major difference between gut-biased and systemic FXR activation is the effect on serum BAs, which for Fex includes a marked change in the relative composition of circulating BAs. A reduction in hepatic Cyp7a1 accompanied by an increase in Cyp7b1 expression shifts BA synthesis away from cholic acid toward chenodeoxycholic acid derivatives, most notably lithocholic acid. While the absolute amount of lithocholic acid did not change following treatment with Fex, the relative amount increased dramatically. Lithocholic acid is a hydrophobic secondary BA and the most potent endogenous ligand for the G protein-coupled BA receptor Tgr5 (ref. 33) . Notably, Fex treatment induces metabolic changes similar to those observed with systemic administration of a synthetic Tgr5 agonist 33 . Also, induction of Dio2, a downstream target of Tgr5 (ref. 44) , in BAT with oral Fex implicates this pathway in the increased energy expenditure. Indeed, the metabolic improvements attributed to Fex treatment were tempered in Gpbar1 −/− mice, suggesting that Tgr5 activation is important in meditating selective aspects of Fex signaling. Furthermore, the coordinated browning of the WAT depot provides an independent yet complementary contribution to increased thermogenic capacity [37] [38] [39] [40] .
These studies uncover a new therapeutic avenue to manipulate energy expenditure without appetite changes through intestinally biased activation of the nuclear receptor FXR. Although contrary indications supporting roles for FXR antagonists have been reported 21, 24 , the integral role of FXR in gut homeostasis provides therapeutic advantages in gene activation. Gut-restricted drugs such as Fex inherently offer improved safety profiles, achieving systemic efficacy while avoiding systemic toxicity. In support of the remarkable metabolic improvements achieved via oral Fex treatment, intestinal FXR has been recently identified as a molecular target of vertical sleeve gastrectomy 45 , suggesting that Fex may offer a nonsurgical alternative for the control of metabolic disease.
METHODS
Methods and any associated references are available in the online version of the paper. state, the rate of glucose disappearance (total GDR) is equal to the sum of the rate of endogenous glucose production (that is, HGP) plus the exogenous (cold) GIR. The IS-GDR is equal to the total GDR minus the basal glucose turnover rate.
Statistical analysis. Appropriate statistical analyses were applied, assuming a normal sample distribution, as specified in the figure legends. Statistics were done using Student's t-test. Values were presented as mean ± sd. No samples were excluded from the statistical analyses as investigators were not blinded in the studies. Variances for each group data were calculated and used for Student's t-test. Animal cohort sizes were determined on the basis of similar previous studies.
